Latest revenue
—
as of 2025-12-31
Latest net income
$1.1M
as of 2025-12-31
Net margin
—
as of 2025-12-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Blank Checks (432 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 6, 2026.
Fair value · DCF
DCF: 10-year forecast of free cash flow, discounted at the company's WACC, with a Gordon-growth terminal at year 10. FCF is proxied by last fiscal-year net income (proper FCF needs CFO − CapEx by year, which we don't store yet). Drag the slider to test your own growth thesis — the dominant assumption in any DCF is what comes next, not what the math does with it. Beta defaults to 1.0 when not reported.
Community sentiment
Where do you think AFJKR is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $949.9K
- Enterprise value
- $3.0M
- P/E (trailing)
- 0.9×
- Forward P/E
- —
- P/B
- —
- Dividend yield
- —
- 52-wk high
- —
- 52-wk low
- —
- Beta
- —
- Shares out
- 3.2M
5-year trend
What this company does
Item 1. Business. In this annual report on Form 10-K (the “Annual Report”), references to the “SPAC,” “Aimei Health,” “Company” and to “we,” “us,” and “our” refer to Aimei Health Technology Co., Ltd. Overview We are a blank check company incorporated on April 27, 2023 as a Cayman Islands exempted company and incorporated for the purpose of effecting a merger, share exchange, asset acquisition stock purchase, reorganization, or similar business combination with one or more businesses. We seek to acquire small cap businesses in the biopharmaceutical, medical technology and device industries, as well as in the diagnostic and other services sector. Our efforts in identifying prospective target…
AI summary unavailable — showing raw filing excerpt
Generated from AFJKR's filing dated 2026-05-04
Key risks
Item 1A. Risk Factors. As a smaller reporting company, we are not required to provide the information required by this item. However, the following is a partial list of material risks, uncertainties, and other factors that could have a material effect on us and our operations: Geopolitical conflicts involving Iran, military actions in the Middle East, and the war in Ukraine may adversely affect global economic conditions and cause significant volatility in the trading price of our ordinary shares. The heightened military conflict involving the United States, Israel, and Iran, as well as broader instability in the Middle East, has contributed to significant volatility in global financial and…
AI summary unavailable — showing raw filing excerpt
Generated from AFJKR's filing dated 2026-05-04
Profitability
Return on equity
-71.8%
58.5%Return on assets
8.8%
153.2%Leverage
Debt / equity
-9.20×
82.0%Debt / assets
112.2%
10.0%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q4 2025 2025-12-31 | — | — | $98.1K | -77.9% | — |
Q3 2025 2025-09-30 | — | — | $352.0K | -52.7% | — |
Q2 2025 2025-06-30 | — | — | $425.0K | -30.2% | — |
Q1 2025 2025-03-31 | — | — | $184.7K | -75.6% | — |
Q4 2024 2024-12-31 | — | — | $444.1K | — | — |
Q3 2024 2024-09-30 | — | — | $743.5K | +20650.3% | — |
Q2 2024 2024-06-30 | — | — | $609.1K | — | — |
Q1 2024 2024-03-31 | — | — | $755.5K | — | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Blank Checks · SIC 6770
Your notes
Keep private notes on AFJKR — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
No insider transactions on file for AFJKR in the last 12 months.
Source: SEC Form 4 filings. Backfill runs nightly.
Who owns AFJKR
Institutional value
$374.7K
Total shares held
1.2M
Distinct holders
5
-10 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | JPMORGAN CHASE & CO | 873.0K | $275.0K | — | New |
| 2 | WOLVERINE ASSET MANAGEMENT LLC | 291.4K | $89.8K | -21.2K (-6.8%) | Trimmed |
| 3 | TrueMark Investments, LLC | 14.4K | $4.6K | +0 (+0.0%) | No change |
| 4 | T3 Companies, LLC | 14.7K | $4.5K | +0 (+0.0%) | No change |
| 5 | UBS Group AG | 2.4K | $754 | -1.0K (-29.2%) | Trimmed |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once AFJKR's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.